Phase 2 Macular Degeneration Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with dry age-related macular degeneration (a condition affecting vision in the back of the eye)
- People who are able to understand what the trial involves and agree to take part
- Adults aged over 55 years
- People who are medically well enough to undergo a specific type of eye surgery involving an injection under the retina (the trial site will assess this using a standard health scoring scale)
- Women who have been through menopause, or women who are the partner of a male participant who is unable to father children
- Men who are willing to use barrier contraception (such as condoms) along with spermicide throughout the study
Who may not be able to join:
- People who have a known allergy or sensitivity to eye-dilating drops or a dye called fluorescein (used in eye examinations)
- People who have a serious ongoing medical condition that would make it difficult to take part in the study
- People who currently have cancer or are receiving chemotherapy
- People who have taken medication to suppress the immune system within the past six months
- People with a history of certain infections, including toxoplasmosis, a fungal eye infection called retinal histoplasmosis, or tuberculosis
- People who have taken part in another clinical trial and received an experimental treatment within the past six months
- People who have any other medical condition that the trial doctor believes could interfere with the study, affect safety, or make the results harder to interpret (confirm with trial site)
- Women who are pregnant or breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Rajesh C Rao, M.D., University of Michigan Kellogg Eye Center
Phone: 05184371111
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Safety and tolerability of RPESC-RPE-4W transplantation
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.